Overcoming the challenges of drug development in platinum-resistant ovarian cancer

The definition of “platinum-resistant ovarian cancer” has evolved; it now also reflects cancers for which platinum treatment is no longer an option. Standard of care for platinum-resistant ovarian cancer is single-agent, non-platinum chemotherapy with or without bevacizumab, which produces modest re...

Descripción completa

Detalles Bibliográficos
Autores principales: Eskander, Ramez N., Moore, Kathleen N., Monk, Bradley J., Herzog, Thomas J., Annunziata, Christina M., O’Malley, David M., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616588/
https://www.ncbi.nlm.nih.gov/pubmed/37916177
http://dx.doi.org/10.3389/fonc.2023.1258228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616588/
https://www.ncbi.nlm.nih.gov/pubmed/37916177
http://dx.doi.org/10.3389/fonc.2023.1258228

Ejemplares similares